Want to take quizzes and track your credits?
The coronavirus disease 2019 (COVID-19) pandemic has profoundly disrupted health care delivery in the US.1 The Centers for Disease Control and Prevention noted a 9.1% increase in reported 12-month counts of drug overdose deaths from March 2019 to March 2020, from 67 726 to 73 860.2 On March 13, 2020, a COVID-19 national emergency was declared. To diminish potential barriers to treatment access, 3 days later, federal guidelines on telemedicine use were released, providing authorized practitioners increased flexibility to prescribe buprenorphine to patients with opioid use disorder (OUD) during this public health emergency.3 Other local, state, and federal policy initiatives have also attempted to preserve access to medication treatment for OUD, yet the cumulative outcome of these undertakings is not clear.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: October 24, 2020.
Published Online: December 21, 2020. doi:10.1001/jamainternmed.2020.7497
Corresponding Author: Thuy D. Nguyen, PhD, Department of Health Management and Policy, School of Public Health, University of Michigan, 1415 Washington Heights, M3234 SPH II, Ann Arbor, MI 48109 (email@example.com).
Author Contributions: Dr Nguyen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Nguyen, Gupta, Ziedan, Simon.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Nguyen, Gupta, Ziedan, Simon, Stein.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Nguyen, Gupta, Ziedan.
Administrative, technical, or material support: Simon.
Conflict of Interest Disclosures: Dr Alexander reported being a past chair of the US Food and Drug Administration’s Peripheral and Central Nervous System Advisory Committee; serving as a paid adviser to IQVIA; being a cofounding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and being a member of OptumRx's National P&T Committee. No other disclosures were reported.
Funding/Support: Dr Stein was supported by grant 1R01DA045800-01 from the National Institute on Drug Abuse during the conduct of the study.
Role of the Funder/Sponsor: The data sponsor was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Disclaimer: The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of Symphony Health or any of its affiliated or subsidiary entities.
Additional Information: The data, technology, and services used in the generation of these research findings were supplied pro bono by the COVID-19 Research Database partners, who are acknowledged at https://covid19researchdatabase.org.
You currently have no searches saved.